Biotest recorded revenues of EUR 218 million in 2004
Biotest recorded sales of EUR 218 million last financial year despite the difficult market environment. Sales were down only slightly on the previous year ( - 2%). The primary factors behind this development were the company's conscious reserved reaction on tender markets for plasma products that are characterized by strong price pressure, and the US dollar exchange rate, which did not bide well for export business. In particular, revenues were down in South America, Asia and the Middle East. Revenue growth in Germany (+ 5%) and on European markets (+ 10%) was surpassed by developments on these foreign markets. As a result, the proportion of German to group revenues thus increased slightly in 2004 from 33% to 35%.
The lower revenues were exclusively recorded in the Pharmaceutical division. Revenues in this division totaled EUR 142 million, with 3% less than in the previous year (EUR 146 million).
In contrast, the Diagnostic division was able to stabilize revenues at EUR 76 million, at the same level as the previous year, in the face of a market distinguished by competition for prices. Sales growth in Germany offset a slight downturn abroad.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare
XOMA Announces Planned Retirement of Chief Executive Officer
East German physicians prescribe significantly more high-priced biopharmaceutical medication than West German doctors - 127% higher revenues of pharmaceutical companies per physician and year in the area of former East Germany
Apeiron announces start of phase I trail with cellular anti cancer therapy
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
